Join our daily newsletter At The Bell to receive exclusive market insights
- Medical Developments International (MVP) has announced the CEO, John Sharman, has resigned
- John has been with the company for over 10 years and has played a significant part in its commercial and global success
- Mr Sharman has cited his reasons as being to pursue other business interests
- He will, however, remain in the position for roughly three months to help find a suitable replacement
- Medical Developments is down 6.46 per cent and shares are trading for $7.96 each at market close
Medical Developments International (MVP) has announced the CEO, John Sharman, has resigned.
According to the company, Mr Sharman has chosen to pursue other business interests. He will, however, remain in his position for at least another three months to assist with transitioning a new CEO.
“I’m very grateful for the opportunity given to me by the stakeholders of MVP and would like to personally thank the Chairman, Mr David Williams for his support,” John said.
John has been with the company for over 10 years and has played a significant part in its commercial and global success.
“On behalf of our Board, our staff and our shareholders, I would like to thank John for his outstanding leadership and significant contribution to the company over the last 10 years,” Chairman David Williams said.
“John has been a fantastic leader of our business, we congratulate him on his achievements. While we are sad to see John leave, this is a good opportunity to take the company to another level with a new leader,” David added.
Medical Developments specialises in pain management, asthma, resuscitation and even veterinary equipment.
In late 2019, much of the company’s focus was on its Penthrox pain-relief drug which has been used in Australia for over 40 years. In October 2019, the company decided to take it internationally and launch Penthrox in Italy.
In December, the company submitted an application to have it sold in Russia. However, this can take between one and two years to be approved.
Medical Developments is down 6.46 per cent and shares are trading for $7.96 each at market close.
